Wall Street brokerages expect Meridian Bioscience Inc. (NASDAQ:VIVO) to report sales of $49.74 million for the current quarter, according to Zacks. Two analysts have issued estimates for Meridian Bioscience’s earnings, with the highest sales estimate coming in at $50.03 million and the lowest estimate coming in at $49.44 million. Meridian Bioscience reported sales of $46.81 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 6.3%. The business is scheduled to report its next quarterly earnings results on Wednesday, January 24th.

On average, analysts expect that Meridian Bioscience will report full year sales of $49.74 million for the current financial year, with estimates ranging from $205.20 million to $220.11 million. For the next fiscal year, analysts forecast that the company will post sales of $214.47 million per share, with estimates ranging from $212.93 million to $216.01 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Meridian Bioscience.

Meridian Bioscience (NASDAQ:VIVO) last posted its earnings results on Thursday, November 9th. The company reported $0.15 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.15. Meridian Bioscience had a return on equity of 17.03% and a net margin of 10.74%. The company had revenue of $49.70 million for the quarter, compared to analyst estimates of $48.28 million. During the same quarter last year, the company earned $0.14 earnings per share. The company’s revenue for the quarter was up 5.7% on a year-over-year basis.

A number of research analysts have recently weighed in on VIVO shares. Zacks Investment Research upgraded Meridian Bioscience from a “sell” rating to a “hold” rating in a report on Thursday, October 5th. Canaccord Genuity restated a “hold” rating and issued a $14.00 target price on shares of Meridian Bioscience in a report on Friday, October 13th. Two analysts have rated the stock with a sell rating and four have given a hold rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $11.50.

Meridian Bioscience (NASDAQ:VIVO) opened at $14.60 on Thursday. Meridian Bioscience has a fifty-two week low of $10.75 and a fifty-two week high of $18.58. The company has a quick ratio of 4.04, a current ratio of 5.85 and a debt-to-equity ratio of 0.30. The firm has a market capitalization of $639.58, a P/E ratio of 22.28 and a beta of 0.89.

The firm also recently declared a quarterly dividend, which was paid on Thursday, November 30th. Investors of record on Monday, November 20th were given a dividend of $0.125 per share. This represents a $0.50 dividend on an annualized basis and a dividend yield of 3.42%. The ex-dividend date was Friday, November 17th. Meridian Bioscience’s payout ratio is 98.04%.

Several institutional investors and hedge funds have recently modified their holdings of the stock. GSA Capital Partners LLP increased its position in shares of Meridian Bioscience by 21.7% during the third quarter. GSA Capital Partners LLP now owns 111,317 shares of the company’s stock valued at $1,592,000 after acquiring an additional 19,817 shares during the last quarter. Highbridge Capital Management LLC purchased a new stake in shares of Meridian Bioscience during the third quarter valued at approximately $223,000. OxFORD Asset Management LLP increased its position in shares of Meridian Bioscience by 19.2% during the third quarter. OxFORD Asset Management LLP now owns 158,085 shares of the company’s stock valued at $2,245,000 after acquiring an additional 25,429 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Meridian Bioscience by 4.8% during the third quarter. Dimensional Fund Advisors LP now owns 1,748,848 shares of the company’s stock valued at $25,008,000 after acquiring an additional 80,877 shares during the last quarter. Finally, Hartford Investment Management Co. purchased a new stake in shares of Meridian Bioscience during the third quarter valued at approximately $166,000. 87.03% of the stock is owned by institutional investors.

WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/07/49-74-million-in-sales-expected-for-meridian-bioscience-inc-vivo-this-quarter-3.html.

About Meridian Bioscience

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.